Eisai to Launch Sahne Medical Spray and Sahne Medical Cream

Aug 25, 2020 12:55 JST

Source: Eisai

Relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care products

Sahne Medical Spray is the first OTC drug spray-type lotion containing Heparinoid

TOKYO, Aug 25, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched Sahne Medical Spray and Sahne Medical Cream (both are category-2 OTC drugs, "Sahne Medical") on August 25, 2020 at pharmacies and drugstores throughout Japan, as a new product of the Sahne brand lineup which has been a favored hand care for generations.

Eisai conducted a survey of 1,000 women in their 40s to 50s in April 2020. As a result, it was found that approximately 70% of the subjects felt that the dryness of their skin and/or the dry skin expanse had increased compared to its condition five years ago. Additionally, a number of comments regarding the discomfort of dryness from people with dry skin were received as follows: "The dryness has spread to my thighs, shins, sides, and back.", "I'm distracted just by my underwear rubbing against my skin.", and "My dry skin flakes stick inside my clothes whenever I get undressed, which makes me uncomfortable." It is considered that the skin condition of women after their late 30s requires more reliable moisturizing effects of pharmaceuticals, since the amounts of sebum, natural moisturizing factors, and intercellular lipids in the stratum corneum necessary for water retention of the skin decrease.

"Sahne Medical" is a category-2 OTC drug containing the active ingredient "Heparinoid", which exerts a high moisturizing effect against dry skin (xeroderma) that worsens with age. Heparinoid penetrates into the stratum corneum, increases natural moisturizing factors, and restores the structure of intercellular lipids in the stratum corneum to moisturize dry skin.

There are two types of product lines, spray and cream, which can be selected depending on the part of the body where the product is applied and/or the principles of TPO (time, place and occasion). "Sahne Medical Spray" is the first OTC drug spray-type lotion containing Heparinoid. This product is handy for the consumer to use on the back, side and back of thigh, where it is difficult to apply the medicine by themselves, as it features a container that can be sprayed upside down and a fine mist-like lotion. In addition, the tube-type "Sahne Medical Cream" is recommended for relieving unbearable discomfort of dryness upon going out, as it is convenient to carry.

The Sahne brand has continued to be a gentle companion to the daily lives of many people for 66 years since its launch. With the new launch of Sahne Medical, a pharmaceutical product, Eisai is now able to provide a remedy for skin problems that it had not been able to contribute to before. Eisai will further respond to the wishes of consumers who want to be relieved of the discomfort of dry skin, with the moisturizing effect of pharmaceutical care products and the gentle nature of Sahne products.

Contact:

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: Healthcare & Pharm

Related Press Release

Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year

December 11 2025 18:41 JST

"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List

December 09 2025 17:51 JST

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025

December 04 2025 17:36 JST

New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

December 03 2025 17:19 JST

Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025

December 02 2025 23:01 JST

Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan

November 28 2025 22:00 JST

Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

November 26 2025 18:42 JST

"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom

November 17 2025 21:08 JST

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma

October 30 2025 13:43 JST

Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma

October 28 2025 23:30 JST

More Press release >>

Latest Press Release

Honda Newly Launches "Discover Honda" Content Curation Media Platform
Dec 26, 2025 17:34 JST

Mazda Selected for A List in CDP Water Security for the First Time
Dec 26, 2025 17:19 JST

Fujitsu Develops Fujitsu Kozuchi Physical AI 1.0 for Seamless Integration of Physical and Agentic AI
Dec 26, 2025 14:04 JST

Establishment of DOCOMO Innovation Fund IV, a Corporate Venture Investment Fund
Dec 26, 2025 13:53 JST

The General Incorporated Association Generative AI Japan Announces the Winners of the Japan Generative AI Award 2025
Dec 26, 2025 11:00 JST

BCQ (01963.HK) to Pay RMB 585 Million Cash Dividend, Driving Share Price and Yield Upside
Dec 25, 2025 18:23 JST

Tohoku University and Fujitsu utilize Causal AI to discover superconductivity mechanism of promising new functional material
Dec 23, 2025 14:58 JST

Toward an Athlete- and Planet-Friendly Hakone Ekiden: All Vehicles Provided for the 2026 Race Will Be Electrified
Dec 23, 2025 03:18 JST

MHI Group to Accelerate Development of Digital Talent
Dec 23, 2025 02:57 JST

MHI and EXEO Group Build and Begin Commercial Use of Japan's First GPU Servers with Two-Phase DLC
Dec 23, 2025 02:20 JST

MHI Participates in Demonstration Testing of Vehicle-Infrastructure Integration System for Autonomous Buses in Shimotsuke City
Dec 19, 2025 03:24 JST

NEC and emaratech Collaborate on Biometric Smart Gates Supporting UAE Airport Operations
Dec 19, 2025 03:06 JST

Fujitsu to showcase mobility and physical AI tech at CES 2026
Dec 19, 2025 02:42 JST

Kirin and Fujitsu elucidate a novel gut-brain axis mechanism of citicoline for the first time worldwide through AI-based analysis and experimental validation leveraging drug discovery DX technology
Dec 19, 2025 02:06 JST

TANAKA PRECIOUS METAL GROUP and TANAKA MIRAI Lab. Released Their Fourth Collaborative Musical Work with Sound Wellness Lab (Della): "Precious Metal Orchestra - A Musical Voyage through the Sound of Precious Metals for Christmas" now available for streaming
Dec 18, 2025 22:00 JST

SAKENOVA: 28-Year-Old Master Brewer Pioneers AI-Driven Sake Revolution, Achieving 40% Cost Reduction While Winning International Gold Medals
Dec 15, 2025 23:00 JST

NEC Provides Vehicle Management Equipment for Autonomous Driving at Tokyo International Airport
Dec 15, 2025 19:41 JST

NEC and AEROTHAI Elevate Air Traffic Safety with Advanced Time Sync Solutions from Adtran Oscilloquartz
Dec 15, 2025 19:04 JST

Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership
Dec 15, 2025 08:30 JST

HKTDC 4Q25 Export Confidence Index: 2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion
Dec 12, 2025 23:15 JST

More Latest Release >>